OTCMKTS:EKTAY

Elekta AB (publ) Competitors

$13.81
+0.02 (+0.15 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.81
Now: $13.81
$13.86
50-Day Range
$12.73
MA: $13.33
$13.97
52-Week Range
$8.46
Now: $13.81
$15.19
Volume932 shs
Average Volume3,030 shs
Market Capitalization$5.28 billion
P/E Ratio39.37
Dividend Yield1.03%
Beta0.85

Competitors

Elekta AB (publ) (OTCMKTS:EKTAY) Vs. DGX, GH, NTRA, NVTA, CDNA, and VCYT

Should you be buying EKTAY stock or one of its competitors? Companies in the industry of "medical laboratories" are considered alternatives and competitors to Elekta AB (publ), including Quest Diagnostics (DGX), Guardant Health (GH), Natera (NTRA), Invitae (NVTA), CareDx (CDNA), and Veracyte (VCYT).

Quest Diagnostics (NYSE:DGX) and Elekta AB (publ) (OTCMKTS:EKTAY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Dividends

Quest Diagnostics pays an annual dividend of $2.48 per share and has a dividend yield of 1.9%. Elekta AB (publ) pays an annual dividend of $0.14 per share and has a dividend yield of 1.0%. Quest Diagnostics pays out 37.8% of its earnings in the form of a dividend. Quest Diagnostics has raised its dividend for 1 consecutive years. Quest Diagnostics is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Quest Diagnostics and Elekta AB (publ), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quest Diagnostics010602.38
Elekta AB (publ)21202.00

Quest Diagnostics presently has a consensus price target of $128.8750, indicating a potential downside of 0.95%. Given Quest Diagnostics' stronger consensus rating and higher probable upside, equities analysts plainly believe Quest Diagnostics is more favorable than Elekta AB (publ).

Volatility & Risk

Quest Diagnostics has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Elekta AB (publ) has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.

Profitability

This table compares Quest Diagnostics and Elekta AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quest Diagnostics13.22%19.23%8.77%
Elekta AB (publ)N/AN/AN/A

Earnings and Valuation

This table compares Quest Diagnostics and Elekta AB (publ)'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest Diagnostics$7.73 billion2.21$858 million$6.5619.83
Elekta AB (publ)$1.44 billion3.68$132.74 millionN/AN/A

Quest Diagnostics has higher revenue and earnings than Elekta AB (publ).

Insider and Institutional Ownership

85.7% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 0.0% of Elekta AB (publ) shares are owned by institutional investors. 1.5% of Quest Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Quest Diagnostics beats Elekta AB (publ) on 13 of the 16 factors compared between the two stocks.

Guardant Health (NASDAQ:GH) and Elekta AB (publ) (OTCMKTS:EKTAY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Guardant Health and Elekta AB (publ), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Guardant Health00903.00
Elekta AB (publ)21202.00

Guardant Health presently has a consensus price target of $170.50, indicating a potential upside of 7.57%. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts plainly believe Guardant Health is more favorable than Elekta AB (publ).

Risk & Volatility

Guardant Health has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Elekta AB (publ) has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.

Profitability

This table compares Guardant Health and Elekta AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Guardant Health-67.14%-19.22%-16.37%
Elekta AB (publ)N/AN/AN/A

Earnings and Valuation

This table compares Guardant Health and Elekta AB (publ)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Guardant Health$214.38 million74.25$-75,650,000.00($0.84)-188.69
Elekta AB (publ)$1.44 billion3.68$132.74 millionN/AN/A

Elekta AB (publ) has higher revenue and earnings than Guardant Health.

Institutional and Insider Ownership

84.9% of Guardant Health shares are held by institutional investors. Comparatively, 0.0% of Elekta AB (publ) shares are held by institutional investors. 13.0% of Guardant Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Elekta AB (publ) beats Guardant Health on 7 of the 13 factors compared between the two stocks.

Natera (NASDAQ:NTRA) and Elekta AB (publ) (OTCMKTS:EKTAY) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Profitability

This table compares Natera and Elekta AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Natera-52.11%-53.39%-25.89%
Elekta AB (publ)N/AN/AN/A

Risk & Volatility

Natera has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, Elekta AB (publ) has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.

Institutional and Insider Ownership

94.9% of Natera shares are held by institutional investors. Comparatively, 0.0% of Elekta AB (publ) shares are held by institutional investors. 9.3% of Natera shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Natera and Elekta AB (publ)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Natera$302.33 million30.63$-124,830,000.00($1.99)-53.74
Elekta AB (publ)$1.44 billion3.68$132.74 millionN/AN/A

Elekta AB (publ) has higher revenue and earnings than Natera.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Natera and Elekta AB (publ), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Natera01902.90
Elekta AB (publ)21202.00

Natera presently has a consensus price target of $113.70, indicating a potential upside of 6.31%. Given Natera's stronger consensus rating and higher probable upside, equities analysts plainly believe Natera is more favorable than Elekta AB (publ).

Summary

Natera beats Elekta AB (publ) on 7 of the 13 factors compared between the two stocks.

Invitae (NYSE:NVTA) and Elekta AB (publ) (OTCMKTS:EKTAY) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Profitability

This table compares Invitae and Elekta AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Invitae-183.50%-81.19%-37.28%
Elekta AB (publ)N/AN/AN/A

Volatility and Risk

Invitae has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500. Comparatively, Elekta AB (publ) has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500.

Insider & Institutional Ownership

78.6% of Invitae shares are held by institutional investors. Comparatively, 0.0% of Elekta AB (publ) shares are held by institutional investors. 2.9% of Invitae shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Invitae and Elekta AB (publ)'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invitae$216.82 million34.14$-241,960,000.00($2.28)-16.51
Elekta AB (publ)$1.44 billion3.68$132.74 millionN/AN/A

Elekta AB (publ) has higher revenue and earnings than Invitae.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Invitae and Elekta AB (publ), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Invitae03402.57
Elekta AB (publ)21202.00

Invitae presently has a consensus target price of $49.3333, indicating a potential upside of 31.07%. Given Invitae's stronger consensus rating and higher possible upside, research analysts plainly believe Invitae is more favorable than Elekta AB (publ).

Summary

Invitae beats Elekta AB (publ) on 7 of the 13 factors compared between the two stocks.

CareDx (NASDAQ:CDNA) and Elekta AB (publ) (OTCMKTS:EKTAY) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Profitability

This table compares CareDx and Elekta AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CareDx-11.79%-10.95%-7.94%
Elekta AB (publ)N/AN/AN/A

Volatility and Risk

CareDx has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Elekta AB (publ) has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500.

Insider & Institutional Ownership

0.0% of Elekta AB (publ) shares are held by institutional investors. 3.1% of CareDx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares CareDx and Elekta AB (publ)'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CareDx$127.07 million30.29$-21,970,000.00($0.52)-142.83
Elekta AB (publ)$1.44 billion3.68$132.74 millionN/AN/A

Elekta AB (publ) has higher revenue and earnings than CareDx.

Analyst Recommendations

This is a summary of current ratings and recommmendations for CareDx and Elekta AB (publ), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CareDx01413.00
Elekta AB (publ)21202.00

CareDx presently has a consensus target price of $75.8333, indicating a potential upside of 2.10%. Given CareDx's stronger consensus rating and higher possible upside, research analysts plainly believe CareDx is more favorable than Elekta AB (publ).

Summary

Elekta AB (publ) beats CareDx on 8 of the 14 factors compared between the two stocks.

Veracyte (NASDAQ:VCYT) and Elekta AB (publ) (OTCMKTS:EKTAY) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Insider & Institutional Ownership

0.0% of Elekta AB (publ) shares are held by institutional investors. 8.3% of Veracyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Veracyte and Elekta AB (publ)'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$120.37 million26.81$-12,600,000.00($0.27)-178.41
Elekta AB (publ)$1.44 billion3.68$132.74 millionN/AN/A

Elekta AB (publ) has higher revenue and earnings than Veracyte.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Veracyte and Elekta AB (publ), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Veracyte11602.63
Elekta AB (publ)21202.00

Veracyte presently has a consensus target price of $66.1429, indicating a potential upside of 37.31%. Given Veracyte's stronger consensus rating and higher possible upside, research analysts plainly believe Veracyte is more favorable than Elekta AB (publ).

Profitability

This table compares Veracyte and Elekta AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Veracyte-30.46%-12.27%-10.95%
Elekta AB (publ)N/AN/AN/A

Volatility and Risk

Veracyte has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Elekta AB (publ) has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500.

Summary

Elekta AB (publ) beats Veracyte on 8 of the 13 factors compared between the two stocks.


Elekta AB (publ) Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Quest Diagnostics logo
DGX
Quest Diagnostics
1.9$130.11+0.7%$17.07 billion$7.73 billion16.08Upcoming Earnings
News Coverage
Guardant Health logo
GH
Guardant Health
1.5$158.50+0.4%$15.92 billion$214.38 million-82.98Insider Selling
Unusual Options Activity
Natera logo
NTRA
Natera
1.5$106.95+0.6%$9.26 billion$302.33 million-44.94Insider Selling
Invitae logo
NVTA
Invitae
1.6$37.64+3.8%$7.40 billion$216.82 million-9.68Insider Selling
Gap Down
CareDx logo
CDNA
CareDx
1.0$74.27+3.9%$3.85 billion$127.07 million-161.45Gap Down
Veracyte logo
VCYT
Veracyte
1.4$48.17+17.0%$3.23 billion$120.37 million-69.81Analyst Report
Analyst Revision
News Coverage
BNR
Burning Rock Biotech
0.9$29.56+3.5%$3.09 billionN/A0.00Gap Down
Fulgent Genetics logo
FLGT
Fulgent Genetics
1.4$90.50+0.1%$2.62 billion$32.53 million44.80
GTH
Genetron
0.4$19.95+0.4%$1.76 billion$45.68 million0.00Increase in Short Interest
Castle Biosciences logo
CSTL
Castle Biosciences
1.9$65.51+4.1%$1.64 billion$51.87 million-385.33Insider Selling
News Coverage
Gap Down
DermTech logo
DMTK
DermTech
1.6$43.46+5.7%$1.25 billion$3.36 million-25.72Insider Selling
Analyst Revision
News Coverage
Gap Down
RadNet logo
RDNT
RadNet
1.5$22.22+0.5%$1.16 billion$1.15 billion-105.80
Personalis logo
PSNL
Personalis
1.6$22.19+5.4%$971.26 million$65.21 million-20.93Analyst Report
Gap Down
Renalytix AI logo
RNLX
Renalytix AI
0.6$25.64+4.1%$923.66 millionN/A-160.25
Celcuity logo
CELC
Celcuity
1.0$25.88+2.6%$318.01 millionN/A-30.45Analyst Upgrade
Increase in Short Interest
Gap Down
Centogene logo
CNTG
Centogene
1.2$11.51+1.4%$228.60 million$54.64 million-7.88Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
Exagen logo
XGN
Exagen
1.6$16.62+4.8%$210.58 million$40.39 million-1.35Analyst Report
News Coverage
Gap Down
Progenity logo
PROG
Progenity
1.8$3.37+1.2%$203.05 millionN/A0.00Gap Down
Enzo Biochem logo
ENZ
Enzo Biochem
0.7$3.33+4.2%$160.60 million$76.02 million-7.74Decrease in Short Interest
Gap Down
OpGen logo
OPGN
OpGen
1.3$2.28+1.8%$87.25 million$3.50 million-1.12Analyst Upgrade
Biocept logo
BIOC
Biocept
1.2$4.36+0.7%$58.43 million$5.53 million-1.08Increase in Short Interest
Miragen Therapeutics logo
MGEN
Miragen Therapeutics
1.1$14.76+2.8%$57.68 million$4.46 million-1.39Gap Up
AnPac Bio-Medical Science logo
ANPC
AnPac Bio-Medical Science
0.7$5.00+12.0%$56.01 million$1.56 million-3.09High Trading Volume
News Coverage
Gap Down
Psychemedics logo
PMD
Psychemedics
0.8$6.91+1.2%$38.25 million$37.68 million-10.01
Cancer Genetics logo
CGIX
Cancer Genetics
0.6$3.65+0.3%$14.91 million$7.30 million-1.76
AMS
American Shared Hospital Services
0.1$2.47+2.0%$14.23 million$20.60 million-24.70
AVDX
Avant Diagnostics
0.6$0.03+5.9%$10.78 million$250,000.000.00High Trading Volume
Gap Down
POTN
PotNetwork
0.5$0.01+0.0%$9.51 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
ZICX
Zicix
0.0$0.01+0.0%$5.32 millionN/A0.00
First Choice Healthcare Solutions logo
FCHS
First Choice Healthcare Solutions
0.5$0.16+0.0%$5.27 millionN/A0.00
AGHC
Aeon Global Health
0.4$0.18+11.2%$1.77 million$12.93 million0.00
ACI Global logo
ACGJ
ACI Global
0.0$0.00+0.0%$0.00N/A0.00
CBAI
CBA Florida
0.6$0.01+1.3%$0.00N/A0.00High Trading Volume
Gap Up
GeneLink logo
GNLKQ
GeneLink
0.0$0.00+0.0%$0.00N/A0.00News Coverage
PCHM
PharmChem
0.2$5.25+0.0%$0.00N/A0.00
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.